How Investors May Respond To Personalis (PSNL) CE Mark Win For Its MRD Blood Collection Kits

Simply Wall St.06-15

Earlier this month, Personalis announced clinical data from the 2026 ASCO meeting showing its NeXT Personal assay can detect minimal residual disease at ultra-low levels across six solid tumor types, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643220463?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-06-15 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643220463","market":"us","top_or_hot":-1,"title":"How Investors May Respond To Personalis (PSNL) CE Mark Win For Its MRD Blood Collection Kits","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Personalis announced clinical data from the 2026 ASCO meeting showing its NeXT Personal assay can detect minimal residual disease at ultra-low levels across six solid tumor types, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-investors-may-respond-to-personalis-psnl-ce-mark-win-for\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Personalis (PSNL) CE Mark Win For Its MRD Blood Collection Kits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Personalis (PSNL) CE Mark Win For Its MRD Blood Collection Kits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-15 14:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-investors-may-respond-to-personalis-psnl-ce-mark-win-for><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Personalis announced clinical data from the 2026 ASCO meeting showing its NeXT Personal assay can detect minimal residual disease at ultra-low levels across six solid tumor types, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-investors-may-respond-to-personalis-psnl-ce-mark-win-for\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-investors-may-respond-to-personalis-psnl-ce-mark-win-for","article_id":"2643220463","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-investors-may-respond-to-personalis-psnl-ce-mark-win-for","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643220463","pubTimestamp":1781504282,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Personalis announced clinical data from the 2026 ASCO meeting showing its NeXT Personal assay can detect minimal residual disease at ultra-low levels across six solid tumor types, with strong correlations to relapse and progression risk in colorectal, lung, ovarian, endometrial, melanoma, and renal cancers.\nShortly afterward, the company received CE Mark Class A approval for its EDTA and cfDNA Blood Collection Kits, opening the door for broader use of its MRD ecosystem in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","CE":"塞拉尼斯","BK4588":"碎股","BK4585":"ETF&股票定投概念","PSNL":"Personalis","ISBC":"投资者银行","BK4121":"生命科学工具和服务","BK4109":"特种化学制品"},"translate_title":"投资者对Personalis(PSNL)MRD采血套件赢得CE标志有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"PSNL":1.5,"CE":1.5},"content_text":"Earlier this month, Personalis announced clinical data from the 2026 ASCO meeting showing its NeXT Personal assay can detect minimal residual disease at ultra-low levels across six solid tumor types, with strong correlations to relapse and progression risk in colorectal, lung, ovarian, endometrial, melanoma, and renal cancers. Shortly afterward, the company received CE Mark Class A approval for its EDTA and cfDNA Blood Collection Kits, opening the door for broader use of its MRD ecosystem in clinical trials across the EU and Great Britain. We’ll now examine how CE Mark approval for Personalis’ blood collection kits could reshape its investment narrative and long-term competitive positioning. Outshine the giants: these 14 early-stage AI stocks could fund your retirement.AdvertisementPersonalis Investment Narrative RecapTo own Personalis, you need to believe ultrasensitive MRD testing can convert growing clinical evidence and new geographies into reimbursed, repeat testing at scale. The recent ASCO data and CE Mark for its blood collection kits strengthen the case that NeXT Personal is clinically relevant, but they do not remove the near term risks around reimbursement timing, high cash burn, and exposure to biopharma spending cycles. The CE Mark Class A approval for Personalis’ EDTA and cfDNA Blood Collection Kits is especially relevant because it directly supports broader NeXT Personal use in European clinical trials. This aligns with the key catalyst of expanding test adoption and clinical partnerships, but it also amplifies the execution risk: turning trial activity and technical validation into durable, reimbursed revenue fast enough to offset continued operating losses. Yet against this progress, investors should still weigh the risk that prolonged reimbursement delays and ongoing cash burn could force capital raises that existing shareholders should be aware of... Read the full narrative on Personalis (it's free!)Personalis' narrative projects $162.9 million revenue and $25.4 million earnings by 2029.Uncover how Personalis' forecasts yield a $10.86 fair value, a 13% upside to its current price.Exploring Other PerspectivesPSNL 1-Year Stock Price Chart Some of the lowest estimate analysts were expecting revenue of about US$153.2 million by 2029 and ongoing losses, so compared with the CE Mark catalyst and expanding MRD data, they paint a much more cautious path where reimbursement timing, cash needs, and potential dilution could look very different from what you might expect.Explore 2 other fair value estimates on Personalis - why the stock might be worth just $10.86!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Personalis research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free Personalis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Personalis' overall financial health at a glance.No Opportunity In Personalis?Our top stock finds are flying under the radar-for now. Get in early:Find 44 companies with promising cash flow potential yet trading below their fair value.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643220463","isCrawlerRequest":true}